HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients.

Abstract
This study aimed to evaluate the effectiveness of abatacept (ABA) by anti-cyclic citrullinated peptide (ACPA) status on disease activity as well as radiographic progression in patients with rheumatoid arthritis (RA) in clinical settings. A retrospective cohort study was conducted using data from a multicenter registry. Data from a total of 553 consecutive RA patients treated with intravenous ABA were included. We primarily compared the status of disease activity (SDAI) and radiographic progression (van der Heijde modified total Sharp score: mTSS) between the ACPA-negative (N = 107) and ACPA-positive (N = 446) groups. 'ACPA positive' was defined as ≥ 13.5 U/mL of anti-CCP antibody. Baseline characteristics between groups were similar. The proportion of patients who achieved low disease activity (LDA; SDAI ≤ 11) at 52 weeks was significantly higher in the ACPA-positive group. Multivariate logistic regression analysis identified ACPA positivity as an independent predictor for achievement of LDA at 52 weeks. Drug retention rate at 52 weeks estimated by the Kaplan-Meier curve was significantly higher in the ACPA-positive group. Achievement rate of structural remission (ΔmTSS ≤ 0.5) at 52 weeks was similar between groups. ABA treatment demonstrated a significantly higher clinical response and higher drug retention rate in ACPA-positive patients. Progression of joint destruction was similar between the ACPA-negative and ACPA-positive groups. Close attention should be paid to joint destruction even in patients showing a favorable response to ABA, especially when the ACPA status is positive.
AuthorsDaihei Kida, Nobunori Takahashi, Atsushi Kaneko, Yuji Hirano, Takayoshi Fujibayashi, Yasuhide Kanayama, Masahiro Hanabayashi, Yuichiro Yabe, Hideki Takagi, Takeshi Oguchi, Takefumi Kato, Koji Funahashi, Takuya Matsumoto, Masahiko Ando, Yachiyo Kuwatsuka, Eiichi Tanaka, Hidekata Yasuoka, Yuko Kaneko, Shintaro Hirata, Kosaku Murakami, Yasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Yutaka Yokota, Kenya Terabe, Shuji Asai, Naoki Ishiguro, Toshihisa Kojima
JournalScientific reports (Sci Rep) Vol. 10 Issue 1 Pg. 19717 (11 12 2020) ISSN: 2045-2322 [Electronic] England
PMID33184461 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Citrullinated Protein Antibodies
  • Antirheumatic Agents
  • Peptides, Cyclic
  • cyclic citrullinated peptide
  • Abatacept
Topics
  • Abatacept (therapeutic use)
  • Aged
  • Anti-Citrullinated Protein Antibodies (blood, immunology)
  • Antirheumatic Agents (therapeutic use)
  • Arthritis, Rheumatoid (blood, drug therapy, immunology, pathology)
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Peptides, Cyclic (immunology)
  • Prognosis
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: